Document Detail


Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms.
MedLine Citation:
PMID:  22519966     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Asthma is a common chronic disease characterized by airway inflammation and structural remodeling. Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, is elevated in asthma patients. VEGF contributes to airway responsiveness and remodeling. It has been shown that treatment of asthma patients decreases VEGF levels, and inhibition of VEGF diminishes asthma symptoms in mice. Therefore, polymorphisms in the vascular endothelial growth factor A (VEGFA) gene might be associated with asthma treatment response.
METHODS: This study enrolled 131 children with asthma treated with different therapies - specifically, the inhaled corticosteroid (ICS) fluticasone propionate or the leukotriene receptor antagonist (LTRA) montelukast. We performed an association analysis between improvement of lung function - assessed by measurement of the percentage of the predicted forced expiratory volume in 1 second (%predicted FEV(1)), the ratio between the FEV(1) and the forced vital capacity (FEV(1)/FVC) after 6 and 12 months of treatment, and asthma control after 12 months of treatment - and two polymorphisms, rs2146323 and rs833058, in the VEGFA gene.
RESULTS: Polymorphism rs2146323 A>C in VEGFA was associated with response to ICS therapy. Asthma patients with the AA genotype had a greater improvement in the %predicted FEV(1) than those with the AC or CC genotype (p = 0.018). Conversely, the AA genotype in rs2146323 was associated with uncontrolled asthma in patients regularly receiving LTRA therapy (p = 0.020) and a worse FEV(1)/FVC ratio in patients who episodically used LTRA therapy (p = 0.044). Furthermore, polymorphism rs833058 C>T was associated with treatment response to episodically used LTRA therapy. A subgroup of patients with the TT genotype had an improvement in the %predicted FEV(1), compared with no improvement in patients with the CT or CC genotype (p = 0.029).
CONCLUSIONS: Our results showed that treatment response to commonly used asthma therapies (ICS or LTRA) is associated with polymorphisms rs2146323 and rs833058 in VEGFA. With additional replication of this preliminary study, our findings could contribute to the development of individualized asthma therapy.
Authors:
Mateja Balantic; Matija Rijavec; Maja Skerbinjek Kavalar; Stanislav Suskovic; Mira Silar; Mitja Kosnik; Peter Korosec
Related Documents :
12077636 - Management of hemorrhoidal disease in patients with chronic spinal cord injury.
2693076 - Efficacy of ethanolamine and polidocanol in the eradication of esophageal varices. a pr...
17496006 - Improved detection and localization of lower gastrointestinal hemorrhage using subtract...
2788116 - Sucralfate for the prevention of early rebleeding following injection sclerotherapy for...
17426216 - Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema.
7209296 - Nasal mucoliliary clearance in patients with septal deviation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-31     Completed Date:  2012-11-19     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  173-80     Citation Subset:  IM    
Affiliation:
University Clinic of Pulmonary and Allergic Diseases, Golnik, Slovenia. matija.rijavec@klinika-golnik.si
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetates / therapeutic use
Androstadienes / therapeutic use
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*,  genetics*,  physiopathology
Child
Female
Forced Expiratory Volume / drug effects
Humans
Male
Polymorphism, Single Nucleotide
Quinolines / therapeutic use
Treatment Outcome
Vascular Endothelial Growth Factor A / genetics*
Chemical
Reg. No./Substance:
0/Acetates; 0/Androstadienes; 0/Anti-Asthmatic Agents; 0/Quinolines; 0/Vascular Endothelial Growth Factor A; CUT2W21N7U/fluticasone; MHM278SD3E/montelukast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups.
Next Document:  Intrinsic Terahertz Plasmons and Magnetoplasmons in Large Scale Monolayer Graphene.